Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | IDH2 |
Variant | R172G |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | IDH2 R172G lies within the active site of the Idh2 protein (PMID: 19228619). R172G results in decreased Idh2 enzymatic activity as indicated by reduced production of NADPH in culture (PMID: 21326614, PMID: 19228619), and confers a gain of function to Idh2 as indicated by production of 2HG (R(-)-2-hydroxyglutarate), and leads to activation of HIF-1-alpha signaling and nuclear accumulation of beta-catenin in cell culture (PMID: 22309944, PMID: 21326614). |
Associated Drug Resistance | |
Category Variants Paths |
IDH2 mutant IDH2 act mut IDH2 R172G IDH2 mutant IDH2 R172X IDH2 R172G |
Transcript | NM_002168.4 |
gDNA | chr15:g.90088607T>C |
cDNA | c.514A>G |
Protein | p.R172G |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002168.3 | chr15:g.90088607T>C | c.514A>G | p.R172G | RefSeq | GRCh38/hg38 |
NM_002168.4 | chr15:g.90088607T>C | c.514A>G | p.R172G | RefSeq | GRCh38/hg38 |
NM_002168 | chr15:g.90088607T>C | c.514A>G | p.R172G | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03953898 | Phase II | Olaparib | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | Active, not recruiting | USA | 0 |
NCT04164901 | Phase III | Vorasidenib | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | Active, not recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | 1 |